Development of biologicals for the therapy of lupus erythematosus

References

• Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet357(9261), 1027–1032 (2001).
   PubMed Web of Science ®Google Scholar
• Teixeira M, Ferreira M, Alves R, Selores M. Lupus erythematosus tumidus: an underestimated entity. Lupus15(5), 296–300 (2006).
   PubMedGoogle Scholar
• Russell AI, Cunninghame Graham DS, Shepherd C et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum. Mol. Genet.13(1), 137–147 (2004).
   PubMed Web of Science ®Google Scholar
• Prokunina L, Castillejo-Lopez C, Oberg F et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet.32(4), 666–669 (2002).
   PubMed Web of Science ®Google Scholar
• Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and systemic lupus erythematosus: a new perspective. J. Immunol.174(11), 6599–6607 (2005).
   PubMed Web of Science ®Google Scholar
• Bijl M, Kallenberg CG. Ultraviolet light and cutaneous lupus. Lupus15(11), 724–727 (2006).
   PubMed Web of Science ®Google Scholar
• Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case–control study. Arthritis Rheum.46(7), 1830–1839 (2002).
   PubMedGoogle Scholar
• Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J. Clin. Epidemiol.55(10), 982–989 (2002).
   PubMedGoogle Scholar
• Cooper GS, Parks CG. Occupational and environmental exposures as risk factors for systemic lupus erythematosus. Curr. Rheumatol. Rep.6(5), 367–374 (2004).
   PubMedGoogle Scholar
• Cooper GS, Parks CG, Treadwell EL et al. Occupational risk factors for the development of systemic lupus erythematosus. J. Rheumatol.31(10), 1928–1933 (2004).
   PubMed Web of Science ®Google Scholar
• Weening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int.65(2), 521–530 (2004).
   PubMed Web of Science ®Google Scholar
• Sanna G, Bertolaccini ML, Cuadrado MJ et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol.30(5), 985–992 (2003).
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Aotsuka S, Satoh T. Clinical and laboratory features of lupus patients with complicating pulmonary disease. Respir. Med.93(2), 95–101 (1999).
   PubMed Web of Science ®Google Scholar
• Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med.349(25), 2399–2406 (2003).
   PubMed Web of Science ®Google Scholar
• Doria A, Iaccarino L, Sarzi-Puttini P et al. Cardiac involvement in systemic lupus erythematosus. Lupus14(9), 683–686 (2005).
   PubMed Web of Science ®Google Scholar
• Zonana-Nacach A, Jimenez-Balderas FJ. Avascular necrosis of bone associated with primary antiphospholipid syndrome: case report and literature review. J. Clin. Rheumatol.10(4), 214–217 (2004).
   PubMedGoogle Scholar
• Ibanez D, Gladman DD, Urowitz MB. Adjusted mean systemic lupus erythematosus disease activity index-2K is a predictor of outcome in SLE. J. Rheumatol.32(5), 824–827 (2005).
   PubMed Web of Science ®Google Scholar
• Walsh M, James M, Jayne D et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol.2(5), 968–975 (2007).
   PubMed Web of Science ®Google Scholar
• D’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet369(9561), 587–596 (2007).
   PubMed Web of Science ®Google Scholar
• Lovstrom B, Backlin C, Sundstrom C, Ekbom A, Lundberg IE. A closer look at non Hodgkin’s lymphoma cases in a national Swedish Systemic Lupus Erythematosus cohort – a nested case–control study. Ann. Rheum. Dis. (2007).
   Google Scholar
• Bernatsky S, Ramsey-Goldman R, Isenberg D et al. Hodgkin’s lymphoma in systemic lupus erythematosus. Rheumatology (Oxford)46(5), 830–832 (2007).
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ.10(1), 124–133 (2003).
   PubMed Web of Science ®Google Scholar
• Reilly CM, Gilkeson GS. Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. Immunol. Res.25(2), 143–153 (2002).
   PubMed Web of Science ®Google Scholar
• Lu Q, Shen N, Li XM, Chen SL. Genomic view of IFN-α response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immun. (2007).
   Google Scholar
• Takeuchi T, Tsuzaka K, Abe T et al. T cell abnormalities in systemic lupus erythematosus. Autoimmunity38(5), 339–346 (2005).
   PubMed Web of Science ®Google Scholar
• Singh RR. IL-4 and many roads to lupuslike autoimmunity. Clin. Immunol.108(2), 73–79 (2003).
   PubMedGoogle Scholar
• Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol.56(7), 481–490 (2003).
   PubMed Web of Science ®Google Scholar
• Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC. Altered signal transduction in SLE T cells. Rheumatology (Oxford)46(10), 1525–1530 (2007).
   PubMed Web of Science ®Google Scholar
• Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr. Opin. Immunol.18(6), 676–682 (2006).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity25(3), 383–392 (2006).
   PubMed Web of Science ®Google Scholar
• Wenzel J, Uerlich M, Worrenkamper E et al. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br. J. Dermatol.153(5), 1011–1015 (2005).
   PubMed Web of Science ®Google Scholar
• Selmi C, Lleo A, Zuin M et al. Interferon α and its contribution to autoimmunity. Curr. Opin. Investig. Drugs7(5), 451–456 (2006).
   PubMed Web of Science ®Google Scholar
• Kikawada E, Lenda DM, Kelley VR. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-γ expression, and diminishes systemic pathology. J. Immunol.170(7), 3915–3925 (2003).
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Yamagata T, Nozaki Y et al. Blockade of IL-18 receptor signaling delays the onset of autoimmune disease in MRL-Faslpr mice. J. Immunol.173(8), 5312–5318 (2004).
   PubMedGoogle Scholar
• Peng SL, Moslehi J, Craft J. Roles of interferon-γ and interleukin-4 in murine lupus. J. Clin. Invest.99(8), 1936–1946 (1997).
   PubMed Web of Science ®Google Scholar
• Yin Z, Bahtiyar G, Zhang N et al. IL-10 regulates murine lupus. J. Immunol.169(4), 2148–2155 (2002).
   PubMed Web of Science ®Google Scholar
• Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology119(3), 296–305 (2006).
   PubMed Web of Science ®Google Scholar
• Anolik J, Sanz I, Looney RJ. B cell depletion therapy in systemic lupus erythematosus. Curr. Rheumatol. Rep.5(5), 350–356 (2003).
   PubMedGoogle Scholar
• Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum.46(10), 2673–2677 (2002).
   PubMed Web of Science ®Google Scholar
• Ahuja A, Shupe J, Dunn R et al. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol.179(5), 3351–3361 (2007).
   PubMed Web of Science ®Google Scholar
• Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther.8(3), R83 (2006).
   PubMed Web of Science ®Google Scholar
• Anolik JH, Barnard J, Owen T et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum.56(9), 3044–3056 (2007).
   PubMed Web of Science ®Google Scholar
• Yan J, Harvey BP, Gee RJ, Shlomchik MJ, Mamula MJ. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J. Immunol.177(7), 4481–4487 (2006).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamamoto K, Takeuchi T et al. A multicenter Phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol.17(3), 191–197 (2007).
   PubMedGoogle Scholar
• Rituxan warning. FDA Consum.41(3), (2007).
   Google Scholar
• Dorner T, Kaufmann J, Wegener WA et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther.8(3), R74 (2006).
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Youinou P. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin. Biol. Ther.6(9), 943–949 (2006).
   PubMed Web of Science ®Google Scholar
• Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr. Opin. Immunol.19(3), 327–336 (2007).
   PubMed Web of Science ®Google Scholar
• Stohl W. A therapeutic role for BLyS antagonists. Lupus13(5), 317–322 (2004).
   PubMed Web of Science ®Google Scholar
• Ding C, Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr. Opin. Investig. Drugs7(5), 464–472 (2006).
   PubMed Web of Science ®Google Scholar
• Grammer AC, Lipsky PE. CD154–CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum.46(6), 1417–1429 (2002).
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum.46(12), 3251–3258 (2002).
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum.48(3), 719–727 (2003).
   PubMed Web of Science ®Google Scholar
• Shirota Y, Yarboro C, Sims G. The impact of in vivo anti-IL-6 receptor blockade on circulating T- and B-cell subsets in patients with systemic lupus erythematosus. Presented at: 69th Annual Meeting of the American College of Rheumatology. San Diego, CA, USA, 12–17 November 2005 (Abstract 1884).
   Google Scholar
• al Janadi M, al Dalaan A, al Balla S, al Humaidi M, Raziuddin S. Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell–B cell antibody synthesis. J. Clin. Immunol.16(4), 198–207 (1996).
   PubMedGoogle Scholar
• Grondal G, Gunnarsson I, Ronnelid J et al. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol.18(5), 565–570 (2000).
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Lefebvre C, Vanden Berghe M et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus4(5), 393–395 (1995).
   PubMed Web of Science ®Google Scholar
• Park YB, Lee SK, Kim DS et al. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol.16(3), 283–288 (1998).
   PubMed Web of Science ®Google Scholar
• van der Linden MW, Westendorp RG, Sturk A, Bergman W, Huizinga TW. High interleukin-10 production in first-degree relatives of patients with generalized but not cutaneous lupus erythematosus. J. Investig. Med.48(5), 327–334 (2000).
   PubMedGoogle Scholar
• Llorente L, Richaud-Patin Y, Garcia-Padilla C et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum.43(8), 1790–1800 (2000).
   PubMed Web of Science ®Google Scholar
• Aringer M, Smolen JS. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus13(5), 344–347 (2004).
   PubMed Web of Science ®Google Scholar
• Aringer M, Steiner G, Graninger WB et al. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum.56(1), 274–279 (2007).
   PubMed Web of Science ®Google Scholar
• Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum.50(10), 3161–3169 (2004).
   PubMed Web of Science ®Google Scholar
• Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med. J. Aust.183(4), 205–208 (2005).
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Adalimumab: a review of side effects. Expert Opin. Drug Saf.4(4), 637–641 (2005).
   PubMedGoogle Scholar
• Dalpke AH, Schafer MK, Frey M et al. Immunostimulatory CpG-DNA activates murine microglia. J. Immunol.168(10), 4854–4863 (2002).
   PubMed Web of Science ®Google Scholar
• Dalpke A, Zimmermann S, Heeg K. CpG-oligonucleotides in vaccination: signaling and mechanisms of action. Immunobiology204(5), 667–676 (2001).
   PubMed Web of Science ®Google Scholar
• Raz E, Watanabe A, Baird SM et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc. Natl Acad. Sci. USA90(10), 4523–4527 (1993).
   PubMed Web of Science ®Google Scholar
• Raz E, Dudler J, Lotz M et al. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus4(4), 286–292 (1995).
   PubMed Web of Science ®Google Scholar
• Gutierrez-Ramos JC, Andreu JL, Revilla Y, Vinuela E, Martinez C. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature346(6281), 271–274 (1990).
   PubMed Web of Science ®Google Scholar
• Huggins ML, Huang FP, Xu D, Lindop G, Stott DI. Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-β1 gene therapy using attenuated Salmonella typhimurium as gene carrier. Lupus8(1), 29–38 (1999).
   PubMedGoogle Scholar
• Huggins ML, Huang FP, Xu D, Lindop G, Stott DI. Modulation of the autoimmune response in lupus mice by oral administration of attenuated Salmonella typhimurium expressing the IL-2 and TGF-β genes. Ann. NY Acad. Sci.815, 499–502 (1997).
   PubMedGoogle Scholar
• Tsuzaka K, Setoyama Y, Yoshimoto K et al. A splice variant of the TCR ζ mRNA lacking exon 7 leads to the down-regulation of TCR ζ, the TCR/CD3 complex, and IL-2 production in systemic lupus erythematosus T cells. J. Immunol.174(6), 3518–3525 (2005).
   PubMed Web of Science ®Google Scholar
• Nambiar MP, Fisher CU, Warke VG et al. Reconstitution of deficient T cell receptor ζ chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum.48(7), 1948–1955 (2003).
   PubMedGoogle Scholar
• Horwitz DA, Zheng SG, Gray JD et al. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin. Immunol.16(2), 135–143 (2004).
   PubMed Web of Science ®Google Scholar
• Zheng SG, Wang JH, Koss MN et al. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-β suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J. Immunol.172(3), 1531–1539 (2004).
   PubMed Web of Science ®Google Scholar
• Fujio K, Okamoto A, Tahara H et al. Nucleosome-specific regulatory T cells engineered by triple gene transfer suppress a systemic autoimmune disease. J. Immunol.173(3), 2118–2125 (2004).
   PubMed Web of Science ®Google Scholar
• Lawson BR, Prud'homme GJ, Chang Y et al. Treatment of murine lupus with cDNA encoding IFN-γR/Fc. J. Clin. Invest.106(2), 207–215 (2000).
   PubMed Web of Science ®Google Scholar
• Balomenos D, Rumold R, Theofilopoulos AN. Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest.101(2), 364–71 (1998).
   PubMed Web of Science ®Google Scholar
• Hagiwara E, Okubo T, Aoki I et al. IL-12-encoding plasmid has a beneficial effect on spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. Cytokine12(7), 1035–1041 (2000).
   PubMedGoogle Scholar
• Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol.8(4), 345–350 (2007).
   PubMed Web of Science ®Google Scholar
• Bossu P, Neumann D, Del Giudice E et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc. Natl Acad. Sci. USA100(24), 14181–14186 (2003).
   PubMed Web of Science ®Google Scholar
• Esfandiari E, McInnes IB, Lindop G et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J. Immunol.167(9), 5338–5347 (2001).
   PubMed Web of Science ®Google Scholar
• Neumann D, Tschernig T, Popa D et al. Injection of IL-12- and IL-18-encoding plasmids ameliorates the autoimmune pathology of MRL/Mp-Tnfrsf6lpr mice: synergistic effect on autoimmune symptoms. Int. Immunol.18(12), 1779–1787 (2006).
   PubMedGoogle Scholar
• Vielhauer V, Anders HJ, Schlondorff D. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin. Nephrol.27(1), 81–97 (2007).
   PubMed Web of Science ®Google Scholar
• Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J. Exp. Med.190(12), 1813–1824 (1999).
   PubMed Web of Science ®Google Scholar
• Tesch GH, Schwarting A, Kinoshita K et al. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J. Clin. Invest.103(1), 73–80 (1999).
   PubMed Web of Science ®Google Scholar
• Shimizu S, Nakashima H, Masutani K et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford)43(9), 1121–1128 (2004).
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Kohno M, Sasaki M et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum.48(9), 2555–2566 (2003).
   PubMed Web of Science ®Google Scholar
• Shimizu S, Nakashima H, Karube K, Ohshima K, Egashira K. Monocyte chemoattractant protein-1 activates a regional Th1 immunoresponse in nephritis of MRL/lpr mice. Clin. Exp. Rheumatol.23(2), 239–242 (2005).
   PubMedGoogle Scholar
• Fan GC, Singh RR. Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J. Exp. Med.196(6), 731–741 (2002).
   PubMedGoogle Scholar
• Ferrera F, Hahn BH, Rizzi M et al. Protection against renal disease in (NZB × NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. Arthritis Rheum.56(6), 1945–1953 (2007).
   PubMed Web of Science ®Google Scholar
• Lehnhardt FG, Scheid C, Holtik U et al. Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with recurrent longitudinal myelitis and cerebral infarction. Lupus15(4), 240–243 (2006).
   PubMed Web of Science ®Google Scholar